Commentary Open Access
Volume 2 | Issue 3 | DOI: https://doi.org/10.46439/allergy.2.027
Multiplexing with a new dimension for serological analysis of infectious diseases
Shubhagata Das1,*, Stephen Angeloni1, Sherry Dunbar1
- 1Luminex Corporation, Austin, TX, USA
Corresponding Author
Shubhagata Das, sdas@luminexcorp.com
Received Date: September 14, 2021
Accepted Date: October 28, 2021
Das S, Angeloni S, Dunbar S. Multiplexing with a new dimension for serological analysis of infectious diseases. J Allergy Infect Dis 2021; 2(3):73-74.
Copyright: © 2021 Das S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Recommended Articles
Surgical smoke and SARS-CoV-2 transmission
The protection of health care workers from nosocomial infection is a paramount consideration in the current pandemic involving severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Not only is prevention of viral transmission the most effective means to lessen the public health impact of coronavirus disease 2019 (COVID-19), but also both quarantine and illness – that disproportionately affect health care workers – have devastating effects on the ability of hospitals to adequately care for increased patient loads.
mTOR: A possible therapeutic target against SARS-CoV-2 infection
The recent pandemic of SARS-CoV-2 has emerged as a health emergency to develop effective therapeutic strategies for restricting deadly disease, COVID-19. SARS-CoV-2 infects cells by the endocytosis process via receptor-mediated binding and priming by cellular proteases.
Antenatal SARS-COV-2 exposure leading to multisystem inflammatory syndrome (MIS-N) presenting with neonatal encephalopathy
A 22-day-old male neonate was admitted to the neonatal intensive care unit (NICU) with complaints of abnormal movements, fever, breath holding spells, refusal and bluish discoloration of skin. He was born at term with a birthweight of 2·72 kg to a mother with a history of positive polymerase chain reaction for SARS-Coronavirus-2 (SARS-COV-2) virus (RT-PCR-positive), asymptomatic 2019 novel coronavirus disease (COVID-19) at 32-33 weeks gestation, which did not require any supportive measures.
Risk of aerosol transmission of SARS-CoV-2 in cardiovascular care
The ongoing global Coronavirus Disease 2019 (COVID19) pandemic has enormous social and economic impact. COVID19 is caused by the Coronavirus Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and is characterized by a high transmission rate and increased mortality from acute respiratory distress syndrome compared to other viruses.
Commentary: SARS-CoV-2 new variants: Characteristic features and impact on the efficacy of different vaccines
A recent article published by Abbas et al. in the Journal of Biomedicine and Pharmacotherapy systematically revealed about the vaccines developed against the recent pandemic agents SARS-CoV-2 and its variants [1]. The authors insightfully provided an overview on the distinct features of the SARS-CoV-2 new variants, the associated mortality rate, hospitalization, re-infection and finally the efficacy of different vaccines.